Aradhana Sarin: Yes, so just to clarify, we haven’t dropped our tax rate. Again, tax is something that — its really hard to pin down quarter-on-quarter. We have maintained sort of our guidance for the full year. And the quarter-on-quarter variability happens depending on the geographic mix, the business mix, the progression of certain tax audits, the carryover from prior periods and changes in tax laws, et cetera. So, I don’t think you should read too much into that for the full year. As it relates to going forward, again, in the U.K., you realize that we do have an expected tax increase. At the same time, we manage our tax rate for the long-term and we are continuously doing business planning and tax planning to manage our — the tax rate in the best possible manner. So that’s an exercise that we continuously undertake.
Pascal Soriot: Thank you, Aradhana. Michael Leuchten, UBS. Michael, over to you.
Michael Leuchten: I’m sorry, Pascal. Thank you for taking my question. I just wanted to go back to LATIFY. As Susan mentioned and wondered if you could comment on how to think about that in the context of Lung01 and Lung07. There is a way to think about the ADCs in terms of cumulated toxicities over time, but it looks like you’re looking at the potential IO resistance in a different way in the LATIFY trials. So just wondering if I’m over interpreting that, or not. Thank you.
Susan Galbraith: I just want to make sure that I understand your question correctly. So the LATIFY study is designed as a randomized comparison versus second-line docetaxel, looking at the combination of ceralasertib and durvalumab, and it does include potential to overcome resistance to IO therapy in patients who have progressed on a prior IO based regimen in the first-line setting.
Michael Leuchten: Would it not create a potential conflict and where you think data could fit longer term in terms of sequencing over time? That’s what I was asking.
Susan Galbraith: Right. Okay. So I think first of all, there are lots of opportunities within lung cancer and options that patients are going to want to have. There’s also an awful lot of patients that are going to have progressed prior — after prior checkpoint inhibition, not just in lung cancer, but in other settings. So I just see this as one of the options that we can offer to patients in that second-line setting. And obviously, our ambition for Dato is to move that into the early lines of lung cancer. So I don’t see in long-term as a conflict, but as just a range of options that we’re going to have for patients in lung cancer.
Pascal Soriot: Thank you, Susan. Jo Walton. Go ahead, Jo. Jo, we cannot hear you. I don’t know if you’re on mute. Go ahead.
Jo Walton: Can you hear me now?
Pascal Soriot: Yes. Perfect. Go. Go ahead.
Jo Walton: Thank you very much. Two quick ones, please. For , I wonder if you could tell us about how you think about gross margin going forward. You outlined that you were looking at your footprint. And you were really looking at the how to optimize that. How should we think in terms of potential improvement? You’re already at over 80% gross margin. What could that get to in the future? And a second question on Tagrisso. We’ve all been very excited about the opportunity to move into adjuvant. It hasn’t really sort of picked up yet in the sense of patients taking it. I wonder if you could give us an update on levels of awareness in the adjuvant market and the degree to which Tagrisso sales are growing there? Thank you.
Pascal Soriot: You want to take the ?
